Drugs / INVOPRESSIN
INVOPRESSIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05309200 | Apr 2022 → Sep 2023 | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | Ocelot Bio, Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INVOPRESSIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314925 ↗ |
| Known as | Invopressina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314925 ↗ |
| Known as | Invopressine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314925 ↗ |
| Known as | OCE-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05309200 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314925 ↗ |
| Route | Intravenous | “used for intravenous infusion” NCT05309200 ↗ |